Table 2.

Data extraction

Study design
• Study name, author and year of publication  • Study design  • Study period  • Inclusion/exclusion criteria  • Country  • Settings  • HCV treatment regimen  • Definition of cirrhosis detection  • HCV RNA quantification limit  • Population analysed  • Attrition and selection bias
Trial characteristics
• Type of publication  • Type of study  • Treatment regimen  • Treatment duration  • Ribavirin
Patient characteristics
• Proportion of men  • Ethnicity (Caucasian/Asian)  • Body-mass index  • GT3 sample size at baseline  • Treatment-naïve patients  • CKD stages  • Dialysis  • Renal transplantation  • Concomitant treatment with proton pump inhibitor (PPI)
Disease characteristics
• HCV RNA  • Baseline resistance-associated variants/substitutions (RAV)  • Human immunodeficiency virus (HIV) co-infection  • Liver transplantation  • Cirrhosis (compensated/decompensated)  • MELD score  • Child-Pugh score  • Liver disease severity (F0/F1/F2/F3/F4)
Treatment outcomes
• Rates of SVR (SVR4, SVR12, SVR24 and/or unspecified SVR)  • 95% confidence interval (calculated from SVR data, where reported)  • Rates of relapse after treatment  • Type of relapse  • Treatment discontinuation  • Serious adverse events (SAEs)

CKD chronic kidney disease, GT3 genotype 3, HCV hepatitis C virus, MELD model for end-stage liver disease, SVR sustained virological response